Cambridge, MA — July 14, 2025 — Alden Scientific, the leader in AI based multi-omic innovation and precision health technologies, announced the acquisition of Oncimmune Germany GmbH, a pioneering immunodiagnostics and biomarker company known for its leading antibody and autoantibody biomarker discovery platform, ImmunoINSIGHTS™. The acquisition provides Alden Scientific unique access to the world’s largest antigen library covering 9000+ human antigens and multi-species variants.
As part of this strategic asset acquisition, Oncimmune’s German operations will now operate as a standalone, wholly owned subsidiary of Alden Scientific Holdings Incorporated. This move significantly strengthens Alden Scientific’s platform capabilities and enables the company to deliver insights to individuals and research partners focused on immune-mediated diseases.
“Oncimmune has long been recognized for its best-in-class autoantibody profiling platform and its team,” said Eva Maria Janerus, President & Chief Business Officer at Alden Scientific. “The company’s biomarkers improve disease characterization, patient stratification and response prediction, which are all prerequisites for true precision medicine. This acquisition deepens our ability to serve individuals and research partners tackling complex autoimmune disorders and accelerates our shared mission to bring forward new diagnostics and therapeutic insights.”
“I am delighted that Oncimmune Germany GmbH will be joining Alden Scientific,” said Martin Gouldstone, CEO of Oncimmune. “Our first class scientists and platform will now continue to benefit patients and contribute to the development of novel therapeutics and I am excited to see how this will synergise with the multi-omic precision medicine platform that Alden Scientific brings.”
Continuity, Collaboration, and Expanded Value
Alden Scientific is thrilled to continue working with the Oncimmune leadership team, who have positioned the company at the forefront of autoimmune research.
● Martin Gouldstone, CEO of Oncimmune, will continue to lend his expertise in a new role as Strategic Advisor to Alden Scientific.
● Martin Hudson, CFO, and Mike Fisher, Head of Business Development, will remain in their leadership positions to ensure that Oncimmune’s global partners will experience the same world-class customer service and scientific excellence they have always known.
A Foundation for Innovation in Autoimmunity
The acquisition will enable expanded investment in Oncimmune’s core technologies and partnerships while ensuring scientific independence under Alden Scientific’s broader strategic umbrella. The Oncimmune platform, with its unique ability to unlock the immunome using proprietary autoantibody signatures, will play a central role in Alden Scientific’s mission to advance human health through precision biomarker discovery and immune system insights.
For pharma companies, translational scientists, and biomarker leaders, this new chapter means greater access to advanced capabilities, a robust pipeline of innovations in autoimmune disease diagnostics and monitoring, and a renewed emphasis on collaborative development.
“This is a powerful step forward for oncology researchers and patients alike,” said Alexander M.M. Eggermont, MD, PhD., Professor of Clinical & Translational Immunotherapy at UMC Utrecht. “I have worked with Oncimmune on numerous immune-oncology trials and found that their scientific and data analysis expertise in autoantibody profiling to be immensely powerful in helping understand the immune reactions to cancer and its therapy. Combining their immune profiling platform with Alden Scientific’s proteomic expertise opens new doors for understanding disease mechanisms and accelerating precision therapies.”
About Alden Scientific
Alden Scientific is a research institute and health technology company dedicated to unlocking multi-omic insights through AI-powered modeling. Its flagship platform, DigitalMe®, integrates proteomic, genomic, epigenetic, and immune signatures to help predict and prevent disease.
About Oncimmune
Oncimmune is a leader in autoantibody biomarker discovery, providing immunodiagnostics and profiling services to pharmaceutical companies and research institutions globally. Oncimmune’s mission is to develop innovative technologies and solutions to improve the understanding of the immune system leading to more effective, targeted and safer treatments and better diagnosis.
Oncimmune possesses the world’s largest antigen libraries covering 9000+ human antigens and multi-species variants. Developed and curated by immunologists and a team of bioinformaticians, the company offers high content biological insights and analytics powered by proprietary machine learning algorithms, models and deep knowledge mining solutions.
Media contact: media@aldenscientific.com